公开(公告)号：US12024512B2

公开(公告)日：2024-07-02

申请号：US17131024

申请日：2020-12-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro Iwata ,  Yukihiro Ikeda

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07B2200/13

Abstract: Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.

公开(公告)号：US11746109B2

公开(公告)日：2023-09-05

申请号：US16088096

申请日：2017-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro Iwata ,  Masahiro Mizuno ,  Kazuhiro Maeda ,  Tsuneo Yasuma ,  Misaki Homma ,  Yuya Oguro ,  Naohiro Taya ,  Lei Zhu ,  John Daniel Bailey ,  Marianne Langston ,  Siddhesh Dinanath Patil ,  Shruti Gour ,  Lilly Roy

IPC: C07D471/08 ,  A61K9/48

CPC classification number: C07D471/08 ,  A61K9/485 ,  A61K9/4858 ,  C07B2200/13

Abstract: The present disclosure relates to crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (Compound 1) and/or tautomers thereof, wherein Compound 1 has the structure: (I)·0.5H2O; processes for preparing crystalline forms of Compound 1 and/or tautomers thereof; pharmaceutical compositions comprising the crystalline forms; methods of inhibiting a cell division cycle 7 in a mammal comprising administering the crystalline forms; and methods of treating a cell division cycle 7 mediated cancer in a mammal comprising administering the crystalline forms or a pharmaceutical composition comprising the crystalline forms.

公开(公告)号：US10906898B2

公开(公告)日：2021-02-02

申请号：US16074339

申请日：2017-01-31

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kentaro Iwata ,  Yukihiro Ikeda

IPC: C07D471/04

Abstract: Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.

公开(公告)号：US10766876B2

公开(公告)日：2020-09-08

申请号：US15388063

申请日：2016-12-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Koya Kimoto ,  Mitsuo Yamamoto ,  Masato Kitayama ,  Yasuhiro Sawai ,  Miyuki Hohokabe ,  Kentaro Iwata

IPC: C07D401/14 ,  C07C59/54 ,  A61K31/4725 ,  C07C55/08 ,  C07C57/145 ,  C07C59/245 ,  C07C59/265 ,  C07C59/50 ,  C07C65/05 ,  C07C65/10

Abstract: The present invention provides a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and an organic acid capable of forming a cocrystal with the compound.

公开(公告)号：US20170183326A1

公开(公告)日：2017-06-29

申请号：US15388063

申请日：2016-12-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Koya Kimoto ,  Mitsuo Yamamoto ,  Masato Kitayama ,  Yasuhiro Sawai ,  Miyuki Hohokabe ,  Kentaro Iwata

IPC: C07D401/14 ,  C07C65/10 ,  C07C57/145 ,  A61K31/4725 ,  C07C55/08 ,  C07C59/245 ,  C07C59/50 ,  C07C65/05 ,  C07C59/265

Abstract: The present invention provides a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and an organic acid capable of forming a cocrystal with the compound.